Targets › IGKC
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2028.
Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. (UniProt, P01834)
Open in Phaseline: the race on IGKC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peter MacCallum Cancer Centre, Australia | PMCC-COE-KMA anti-KMA (kappa light chain) CAR-T cell therapy | IGKC | Phase 1 | Relapsed/Refractory Multiple Myeloma | Sep 2028 |
Relapsed/Refractory Multiple Myeloma (1)
protein or peptide (1)
Peter MacCallum Cancer Centre, Australia (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.